NextCell Pharma: Updating our view post the trial readout - Redeye
Bildkälla: Stockfoto

NextCell Pharma: Updating our view post the trial readout - Redeye

ProTrans-Young missed its primary endpoint, and the two-year data in the older cohort shows no widening effect. We rebuild our NXTCL-T1D model around the adult indication, with children and adolescents now being considered bull-case optionality. NextCell scores as 'Cheap' on Redeye's value score, and our fair value is updated to SEK0.8 per share

ProTrans-Young missed its primary endpoint, and the two-year data in the older cohort shows no widening effect. We rebuild our NXTCL-T1D model around the adult indication, with children and adolescents now being considered bull-case optionality. NextCell scores as 'Cheap' on Redeye's value score, and our fair value is updated to SEK0.8 per share
Börsvärldens nyhetsbrev